Saxagliptin

A selective DPP-4 inhibitor for the treatment of type 2 diabetes mellitus

Jay Shubrook, Randall Colucci, Guo Aili, Frank Schwartz

Research output: Contribution to journalReview article

11 Citations (Scopus)

Abstract

The prevalence of type 2 diabetes mellitus is high and growing rapidly. Suboptimal glycemic control provides opportunities for new treatment options to improve the morbidity and mortality of this progressive disease. Saxagliptin, a selective DPP-4 inhibitor, increases endogenous incretin levels and incretin acitivty. In controlled clinical trials saxagliptin reduces both fasting and postprandial glucose and works in monotherapy and in combination with metformin, TZDs and sulfonylureas. Saxagliptin has a very favourable side effect profile and may have other beneficial non-glycemic effects. The authors review the current available evidence for the safety, efficacy and saxagliptin's place in therapy for type 2 diabetes mellitus. As understanding of the incretin hormones (GLP-1, GIP) expand we may see additional important non-glycemic effects that may affect the chronic management of type 2 diabetes mellitus.

Original languageEnglish (US)
Pages (from-to)1-12
Number of pages12
JournalClinical Medicine Insights: Endocrinology and Diabetes
Volume4
DOIs
StatePublished - Jan 1 2011
Externally publishedYes

Fingerprint

Incretins
Type 2 Diabetes Mellitus
Glucagon-Like Peptide 1
Metformin
Controlled Clinical Trials
Fasting
Hormones
Morbidity
Safety
Glucose
Mortality
saxagliptin
Therapeutics

Keywords

  • DPP-4 inhibitors
  • Incretin hormones
  • Saxagliptin

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Saxagliptin : A selective DPP-4 inhibitor for the treatment of type 2 diabetes mellitus. / Shubrook, Jay; Colucci, Randall; Aili, Guo; Schwartz, Frank.

In: Clinical Medicine Insights: Endocrinology and Diabetes, Vol. 4, 01.01.2011, p. 1-12.

Research output: Contribution to journalReview article

@article{71aa37085c7742d3a73bd79eacdc4c9a,
title = "Saxagliptin: A selective DPP-4 inhibitor for the treatment of type 2 diabetes mellitus",
abstract = "The prevalence of type 2 diabetes mellitus is high and growing rapidly. Suboptimal glycemic control provides opportunities for new treatment options to improve the morbidity and mortality of this progressive disease. Saxagliptin, a selective DPP-4 inhibitor, increases endogenous incretin levels and incretin acitivty. In controlled clinical trials saxagliptin reduces both fasting and postprandial glucose and works in monotherapy and in combination with metformin, TZDs and sulfonylureas. Saxagliptin has a very favourable side effect profile and may have other beneficial non-glycemic effects. The authors review the current available evidence for the safety, efficacy and saxagliptin's place in therapy for type 2 diabetes mellitus. As understanding of the incretin hormones (GLP-1, GIP) expand we may see additional important non-glycemic effects that may affect the chronic management of type 2 diabetes mellitus.",
keywords = "DPP-4 inhibitors, Incretin hormones, Saxagliptin",
author = "Jay Shubrook and Randall Colucci and Guo Aili and Frank Schwartz",
year = "2011",
month = "1",
day = "1",
doi = "10.4137/CMED.S5114",
language = "English (US)",
volume = "4",
pages = "1--12",
journal = "Clinical Medicine Insights: Endocrinology and Diabetes",
issn = "1178-1173",
publisher = "Libertas Academica Ltd.",

}

TY - JOUR

T1 - Saxagliptin

T2 - A selective DPP-4 inhibitor for the treatment of type 2 diabetes mellitus

AU - Shubrook, Jay

AU - Colucci, Randall

AU - Aili, Guo

AU - Schwartz, Frank

PY - 2011/1/1

Y1 - 2011/1/1

N2 - The prevalence of type 2 diabetes mellitus is high and growing rapidly. Suboptimal glycemic control provides opportunities for new treatment options to improve the morbidity and mortality of this progressive disease. Saxagliptin, a selective DPP-4 inhibitor, increases endogenous incretin levels and incretin acitivty. In controlled clinical trials saxagliptin reduces both fasting and postprandial glucose and works in monotherapy and in combination with metformin, TZDs and sulfonylureas. Saxagliptin has a very favourable side effect profile and may have other beneficial non-glycemic effects. The authors review the current available evidence for the safety, efficacy and saxagliptin's place in therapy for type 2 diabetes mellitus. As understanding of the incretin hormones (GLP-1, GIP) expand we may see additional important non-glycemic effects that may affect the chronic management of type 2 diabetes mellitus.

AB - The prevalence of type 2 diabetes mellitus is high and growing rapidly. Suboptimal glycemic control provides opportunities for new treatment options to improve the morbidity and mortality of this progressive disease. Saxagliptin, a selective DPP-4 inhibitor, increases endogenous incretin levels and incretin acitivty. In controlled clinical trials saxagliptin reduces both fasting and postprandial glucose and works in monotherapy and in combination with metformin, TZDs and sulfonylureas. Saxagliptin has a very favourable side effect profile and may have other beneficial non-glycemic effects. The authors review the current available evidence for the safety, efficacy and saxagliptin's place in therapy for type 2 diabetes mellitus. As understanding of the incretin hormones (GLP-1, GIP) expand we may see additional important non-glycemic effects that may affect the chronic management of type 2 diabetes mellitus.

KW - DPP-4 inhibitors

KW - Incretin hormones

KW - Saxagliptin

UR - http://www.scopus.com/inward/record.url?scp=79952729828&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952729828&partnerID=8YFLogxK

U2 - 10.4137/CMED.S5114

DO - 10.4137/CMED.S5114

M3 - Review article

VL - 4

SP - 1

EP - 12

JO - Clinical Medicine Insights: Endocrinology and Diabetes

JF - Clinical Medicine Insights: Endocrinology and Diabetes

SN - 1178-1173

ER -